[go: up one dir, main page]

DE69133459D1 - Methoden für die ex-vivo replikation und stabile genetische transformation von menschlichen stamm-zellen - Google Patents

Methoden für die ex-vivo replikation und stabile genetische transformation von menschlichen stamm-zellen

Info

Publication number
DE69133459D1
DE69133459D1 DE69133459T DE69133459T DE69133459D1 DE 69133459 D1 DE69133459 D1 DE 69133459D1 DE 69133459 T DE69133459 T DE 69133459T DE 69133459 T DE69133459 T DE 69133459T DE 69133459 D1 DE69133459 D1 DE 69133459D1
Authority
DE
Germany
Prior art keywords
methods
genetic transformation
cells
strain cells
stable genetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69133459T
Other languages
English (en)
Other versions
DE69133459T2 (de
Inventor
G Emerson
F Clarke
O Palsson
M Schwartz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan Ann Arbor
Original Assignee
University of Michigan Ann Arbor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan Ann Arbor filed Critical University of Michigan Ann Arbor
Publication of DE69133459D1 publication Critical patent/DE69133459D1/de
Application granted granted Critical
Publication of DE69133459T2 publication Critical patent/DE69133459T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M23/00—Constructional details, e.g. recesses, hinges
    • C12M23/34—Internal compartments or partitions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
    • C12M29/04—Filters; Permeable or porous membranes or plates, e.g. dialysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
    • C12M29/10—Perfusion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M35/00—Means for application of stress for stimulating the growth of microorganisms or the generation of fermentation or metabolic products; Means for electroporation or cell fusion
    • C12M35/08—Chemical, biochemical or biological means, e.g. plasma jet, co-culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0642—Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/14—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1394—Bone marrow stromal cells; whole marrow
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Sustainable Development (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Clinical Laboratory Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physiology (AREA)
DE69133459T 1990-12-17 1991-12-17 Methoden für die ex-vivo replikation und stabile genetische transformation von menschlichen stamm-zellen Expired - Lifetime DE69133459T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US62834390A 1990-12-17 1990-12-17
US628343 1990-12-17
US73702491A 1991-07-29 1991-07-29
US737024 1991-07-29
US07/740,590 US5399493A (en) 1989-06-15 1991-08-05 Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
US740590 1991-08-05
PCT/US1991/009173 WO1992011355A1 (en) 1990-12-17 1991-12-17 Method for culturing and transforming human stem cell-containing compositions

Publications (2)

Publication Number Publication Date
DE69133459D1 true DE69133459D1 (de) 2005-06-16
DE69133459T2 DE69133459T2 (de) 2006-01-19

Family

ID=27417447

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69133459T Expired - Lifetime DE69133459T2 (de) 1990-12-17 1991-12-17 Methoden für die ex-vivo replikation und stabile genetische transformation von menschlichen stamm-zellen

Country Status (9)

Country Link
US (2) US5399493A (de)
EP (2) EP1473360A3 (de)
JP (5) JPH06505151A (de)
KR (1) KR100225307B1 (de)
AT (1) ATE295412T1 (de)
AU (1) AU687674B2 (de)
CA (1) CA2100268C (de)
DE (1) DE69133459T2 (de)
WO (1) WO1992011355A1 (de)

Families Citing this family (195)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69012601T2 (de) * 1989-02-02 1995-01-19 Joel S Greenberger Gentherapie durch stützgewebebezügliche Zellen.
US5399493A (en) * 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
US5635386A (en) 1989-06-15 1997-06-03 The Regents Of The University Of Michigan Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture
US5605822A (en) * 1989-06-15 1997-02-25 The Regents Of The University Of Michigan Methods, compositions and devices for growing human hematopoietic cells
US5635387A (en) * 1990-04-23 1997-06-03 Cellpro, Inc. Methods and device for culturing human hematopoietic cells and their precursors
US5612211A (en) * 1990-06-08 1997-03-18 New York University Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors
JPH05509096A (ja) * 1990-06-08 1993-12-16 ニューヨークユニバーシティ 骨髄間質細胞及び始原細胞の刺激
US20030125519A1 (en) 1990-08-27 2003-07-03 Peter Besmer Ligand for the c-kit receptor and methods of use thereof
US5744361A (en) * 1991-04-09 1998-04-28 Indiana University Expansion of human hematopoietic progenitor cells in a liquid medium
US5199942A (en) * 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
NL9101680A (nl) * 1991-10-04 1993-05-03 Tno Werkwijze voor het genetisch modificeren van beenmergcellen van primaten, alsmede daarbij bruikbare cellen die recombinante retrovirale vectoren produceren.
AU685743B2 (en) * 1992-03-04 1998-01-29 Regents Of The University Of Michigan, The Methods, compositions and devices for maintaining and growing human stem and/or hematopoietic cells
CA2109729A1 (en) * 1992-03-23 1993-09-30 James G. Bender In vitro-derived human neutrophil precursor cells
US6001803A (en) * 1992-04-23 1999-12-14 Sloan-Kettering Institute For Cancer Research Composition of c-kit ligand, GM-CSF, and TNF-α and method of use
CA2133982C (en) * 1992-04-23 2008-02-12 Peter Besmer Ligand for the c-kit receptor and methods of use thereof
GB9308271D0 (en) * 1993-04-21 1993-06-02 Univ Edinburgh Method of isolating and/or enriching and/or selectively propagating pluripotential animal cells and animals for use in said method
NZ314644A (en) 1993-05-24 2000-11-24 Immunex Corp Use of flt3-ligands as a growth stimulator of stem cells in the transplantation of tissue
US5554512A (en) * 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US5846529A (en) * 1993-08-23 1998-12-08 Nexell Therapeutics, Inc. Infusion of neutrophil precursors for treatment of neutropenia
US6037174A (en) * 1993-08-23 2000-03-14 Nexell Therapeutics, Inc. Preparation of serum-free suspensions of human hematopoietic cells or precursor cells
FR2709309B1 (fr) * 1993-08-25 1995-11-10 Centre Nat Rech Scient Compositions cellulaires, préparation et utilisations thérapeutiques.
US5534423A (en) * 1993-10-08 1996-07-09 Regents Of The University Of Michigan Methods of increasing rates of infection by directing motion of vectors
US5599705A (en) * 1993-11-16 1997-02-04 Cameron; Robert B. In vitro method for producing differentiated universally compatible mature human blood cells
US6190655B1 (en) 1993-12-03 2001-02-20 Immunex Corporation Methods of using Flt-3 ligand for exogenous gene transfer
US5882918A (en) * 1995-08-08 1999-03-16 Genespan Corporation Cell culture incubator
US5622857A (en) * 1995-08-08 1997-04-22 Genespan Corporation High performance cell culture bioreactor and method
EP0743981A4 (de) * 1994-02-09 1999-09-08 Unisyn Technologies Inc Hoch auflösender zellkultur-bioreaktor und seine verwendung
US7294331B2 (en) * 1994-03-07 2007-11-13 Immunex Corporation Methods of using flt3-ligand in hematopoietic cell transplantation
US6242417B1 (en) 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
US5631219A (en) * 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
JPH09501324A (ja) * 1994-03-11 1997-02-10 バクスター、インターナショナル、インコーポレイテッド 細胞保持用の溝を備えた貫流バイオリアクター
US5512480A (en) * 1994-03-11 1996-04-30 Baxter International Inc. Flow-through bioreactor with grooves for cell retention
US7083979B1 (en) * 1994-03-25 2006-08-01 Indiana University Foundation Methods for enhanced retroviral-mediated gene transfer
DE4422667A1 (de) * 1994-06-30 1996-01-04 Boehringer Ingelheim Int Verfahren zur Herstellung und Züchtung hämatopoetischer Vorläuferzellen
WO1996017627A2 (en) * 1994-12-09 1996-06-13 Mosca Joseph D System for the maintenance, growth and differentiation of human and non-human primate pluripotent stem, progenitor and mature bone marrow cells
US5811274A (en) * 1994-12-09 1998-09-22 The Regents Of The University Of Michigan Methods, compositions and apparatus for cell transfection
FR2728584A1 (fr) * 1994-12-22 1996-06-28 Centre Nat Rech Scient Procede de transfert de gene dans des cellules activees a partir d'un etat de repos
US6974571B2 (en) * 1995-03-28 2005-12-13 Thomas Jefferson University Isolated stromal cells and methods of using the same
US5719058A (en) * 1995-04-10 1998-02-17 Merck & Co., Inc. Method for producing a highly enriched population of osteoclast cells
US5792603A (en) * 1995-04-27 1998-08-11 Advanced Tissue Sciences, Inc. Apparatus and method for sterilizing, seeding, culturing, storing, shipping and testing tissue, synthetic or native, vascular grafts
US5846828A (en) * 1995-06-07 1998-12-08 Advanced Tissue Sciences Apparatus and method for sterilizing, seeding, culturing, storing, shipping, and testing tissue, synthetic, or mechanical heart valves orvalve segments
US6121042A (en) * 1995-04-27 2000-09-19 Advanced Tissue Sciences, Inc. Apparatus and method for simulating in vivo conditions while seeding and culturing three-dimensional tissue constructs
US5876956A (en) * 1995-05-15 1999-03-02 Johns Hopkins University School Of Medicine Methods for identification or purification of cells containing an enzymatic intracellular marker
US5674750A (en) * 1995-05-19 1997-10-07 T. Breeders Continuous selective clonogenic expansion of relatively undifferentiated cells
US5925567A (en) * 1995-05-19 1999-07-20 T. Breeders, Inc. Selective expansion of target cell populations
US5688687A (en) * 1995-06-07 1997-11-18 Aastrom Biosciences, Inc. Bioreactor for mammalian cell growth and maintenance
US5843766A (en) * 1995-06-07 1998-12-01 Advanced Tissue Sciences, Inc. Apparatus for the growth and packaging of three dimensional tissue cultures
AU5931896A (en) * 1995-06-07 1996-12-30 Advanced Tissue Sciences, Inc. Apparatus and method for sterilizing, seeding, culturing, st oring, shipping, and testing replacement cartilage tissue co nstructs
US5728581A (en) * 1995-06-07 1998-03-17 Systemix, Inc. Method of expanding hematopoietic stem cells, reagents and bioreactors for use therein
GB9518606D0 (en) 1995-09-12 1995-11-15 Inst Of Psychiatry Neural transplantation
US20020034517A1 (en) * 1995-10-04 2002-03-21 Kenneth Brasel Dendritic cell stimulatory factor
US7361330B2 (en) * 1995-10-04 2008-04-22 Immunex Corporation Methods of using flt3-ligand in the treatment of fibrosarcoma
US7150992B1 (en) 1995-10-04 2006-12-19 Innunex Corporation Methods of preparing dendritic cells with flt3-ligand and antigen
US6060052A (en) 1995-10-30 2000-05-09 Systemix, Inc. Methods for use of Mpl ligands with primitive human hematopoietic stem cells
CN1209836A (zh) * 1995-12-29 1999-03-03 阿尔格公司 骨髓基质细胞的扩展
US6991787B1 (en) 1995-12-29 2006-01-31 Alg Company Methods of preparing bone marrow stromal cells for use in gene therapy
US5763267A (en) * 1996-04-16 1998-06-09 Advanced Tissue Sciences Apparatus for the large scale growth and packaging of cell suspensions and three-dimensional tissue cultures
US6165785A (en) * 1996-05-24 2000-12-26 University Of Cincinnati Bone marrow cultures for developing suppressor and stimulator cells for research and therapeutic applications
ATE299030T1 (de) * 1996-07-10 2005-07-15 Meiji Dairies Corp Verwendung von proteinen aus der mk familie als hämatopoietischer faktor
US6458585B1 (en) 1996-08-14 2002-10-01 Nexell Therapeutics Inc. Cytokine-free culture of dendritic cells
DE69739497D1 (de) 1996-10-01 2009-08-27 Geron Corp Menschlische Telomerase katalytische Untereinheit
US6090622A (en) * 1997-03-31 2000-07-18 The Johns Hopkins School Of Medicine Human embryonic pluripotent germ cells
US6331406B1 (en) 1997-03-31 2001-12-18 The John Hopkins University School Of Medicine Human enbryonic germ cell and methods of use
EP0989855A4 (de) * 1997-05-13 2002-06-12 Osiris Therapeutics Inc Regeneration von knorpel bei osteoarthritis mittels menschlicher mesenchymaler stammzellen
US20020034819A1 (en) * 1998-02-23 2002-03-21 Alan K. Smith Human lineage committed cell composition with enhanced proliferative potential, biological effector function, or both; methods for obtaining same; and their uses
US6835377B2 (en) 1998-05-13 2004-12-28 Osiris Therapeutics, Inc. Osteoarthritis cartilage regeneration
AU4336499A (en) * 1998-06-08 1999-12-30 Osiris Therapeutics, Inc. Regulation of hematopoietic stem cell differentiation by the use of human mesenchymal stem cells
AUPP421298A0 (en) * 1998-06-19 1998-07-09 Fertilitescentrum Ab Method and medium for in vitro culture of human embryos
EP1105463A1 (de) * 1998-08-24 2001-06-13 t. Breeders, Inc. Hemangioblasten enthaltender zellverband und dessen herstellungsverfahren
GB9904281D0 (en) * 1999-02-24 1999-04-21 Reneuron Ltd Transplantation
US20040265285A1 (en) * 1999-04-15 2004-12-30 Monash University Normalization of defective T cell responsiveness through manipulation of thymic regeneration
US20040259803A1 (en) * 1999-04-15 2004-12-23 Monash University Disease prevention by reactivation of the thymus
US20040241842A1 (en) * 1999-04-15 2004-12-02 Monash University Stimulation of thymus for vaccination development
US20040258672A1 (en) * 1999-04-15 2004-12-23 Monash University Graft acceptance through manipulation of thymic regeneration
US20050020524A1 (en) * 1999-04-15 2005-01-27 Monash University Hematopoietic stem cell gene therapy
US20070274946A1 (en) * 1999-04-15 2007-11-29 Norwood Immunoloty, Ltd. Tolerance to Graft Prior to Thymic Reactivation
AUPR074500A0 (en) * 2000-10-13 2000-11-09 Monash University Treatment of t cell disorders
AU7719300A (en) * 1999-09-27 2001-04-30 Ixion Biotechnology, Inc. Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures
AU784538B2 (en) * 1999-12-06 2006-04-27 Geistlich Pharma Ag Use of methylol-containing compounds to treat tumors
US6682902B2 (en) 1999-12-16 2004-01-27 Schering Aktiengesellschaft DNA encoding a novel RG1 polypeptide
EP1276486B2 (de) 2000-04-25 2014-03-05 Osiris Therapeutics, Inc. Wiederherstellung der gelenken mit mesenchymalen stammzellen
NL1017973C2 (nl) * 2000-05-10 2002-11-08 Tristem Trading Cyprus Ltd Inrichting.
US6828145B2 (en) 2000-05-10 2004-12-07 Cedars-Sinai Medical Center Method for the isolation of stem cells by immuno-labeling with HLA/MHC gene product marker
EP1167517A1 (de) * 2000-06-22 2002-01-02 IsoTis N.V. Gewebetechnologie
WO2002000848A1 (en) * 2000-06-28 2002-01-03 Ascendia Ab Dna/rna-embedding medium and method of use
US20060088512A1 (en) * 2001-10-15 2006-04-27 Monash University Treatment of T cell disorders
WO2002046373A1 (en) 2000-12-06 2002-06-13 Hariri Robert J Method of collecting placental stem cells
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
IL157350A0 (en) 2001-02-14 2004-02-19 Anthrogenesis Corp Post-partum mammalian placenta, its use and placental stem cells therefrom
WO2002081620A1 (fr) * 2001-04-03 2002-10-17 Kabushiki Kaisya Advance Systemes de culture cellulaire tridimensionnelle
US7129034B2 (en) * 2001-10-25 2006-10-31 Cedars-Sinai Medical Center Differentiation of whole bone marrow
WO2003050273A1 (fr) * 2001-12-13 2003-06-19 Japan Science And Technology Agency Milieu de culture pour des cellules humaines et methode de culture
JP2005531507A (ja) * 2002-03-02 2005-10-20 ザ ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ストローマ細胞前駆体による抗癌物質の局所的な産生および／または送達方法
WO2003080806A2 (en) * 2002-03-18 2003-10-02 National Jewish Medical And Research Center Method for production of neutrophils and uses therefor
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
CA2487932A1 (en) * 2002-05-30 2003-12-11 Macrogenics, Inc. Cd16a binding proteins and use for the treatment of immune disorders
US7838290B2 (en) * 2002-07-25 2010-11-23 The Scripps Research Institute Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith
MXPA05005673A (es) 2002-11-26 2005-11-23 Anthrogenesis Corp Productos citoterapeuticos, unidades citoterapeuticas y metodos para tratamientos que usan los mismos.
NZ566132A (en) * 2003-02-13 2009-09-25 Anthrogenesis Corp Use of umbilical cord blood to treat inflammation, ParkinsonÆs disease or diabetes
US20050003533A1 (en) 2003-05-08 2005-01-06 Pawel Kalinski Mature type-1 polarized dendritic cells with enhanced IL-12 production and methods of serum-free production and use
US20050023085A1 (en) * 2003-07-30 2005-02-03 Munton Timothy John Lifesaver apparatus
US20080279812A1 (en) * 2003-12-05 2008-11-13 Norwood Immunology, Ltd. Disease Prevention and Vaccination Prior to Thymic Reactivation
US20080226554A1 (en) 2003-12-23 2008-09-18 Mount Sinai Hospital Methods For Detecting Markers Associated With Endometrial Disease or Phase
US20070037276A1 (en) * 2004-02-23 2007-02-15 Eudes Francois Marie De Crecy Continuous culture apparatus with mobile vessel, allowing selection of fitter cell variants and producing a culture in a continuous manner
WO2005118780A1 (en) * 2004-06-04 2005-12-15 Universite Pierre Et Marie Curie - Paris Vi A method for producing red blood cells
JP2008505650A (ja) * 2004-07-12 2008-02-28 ソリン・グループ・イタリア・ソシエタ・ア・レスポンサビリタ・リミタータ ヒト細胞を増殖させるための装置及び方法
US20060035375A1 (en) * 2004-08-16 2006-02-16 Head Jonathan F Method for selectively culturing epithelial or carcinoma cells
US7989001B2 (en) * 2004-09-13 2011-08-02 Untae Kim Method of separating tumor cells with and without lymphotropic metastatic potential in a human carcinoma
DK1645626T3 (da) 2004-09-30 2008-01-21 Reneuron Ltd Cellelinie
WO2006052960A2 (en) * 2004-11-08 2006-05-18 The General Hospital Corporation METHODS AND COMPOSITIONS FOR INCREASING STEM CELL HOMING USING Gαs ACTIVATORS
EP1877547B1 (de) 2005-05-04 2012-08-08 Commonwealth Scientific and Industrial Research Organisation Selektion, kultivierung und erzeugung auf eine zellinie festgelegter hämatopoetischer stammzellen
AU2006304277B2 (en) 2005-10-13 2012-07-05 Celularity Inc. Immunomodulation using placental stem cells
CN101330830B (zh) 2005-10-18 2016-01-20 国家犹太健康中心 条件无限增殖化长期干细胞和制备和使用所述细胞的方法
AU2006315601A1 (en) * 2005-11-14 2007-05-24 Enterprise Partners Venture Capital Stem cell factor therapy for tissue injury
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
EP1976977B1 (de) 2005-12-29 2015-07-08 Anthrogenesis Corporation Stammzell-populationen aus der plazenta
ZA200804718B (en) 2005-12-29 2010-04-28 Anthrogenesis Corp Co-culture of placental stem cells and stem cells from a second source
US7682822B2 (en) 2006-03-31 2010-03-23 Aastrom Biosciences, Inc. Ex vivo generated tissue system
US20080050814A1 (en) * 2006-06-05 2008-02-28 Cryo-Cell International, Inc. Procurement, isolation and cryopreservation of fetal placental cells
US20080064098A1 (en) * 2006-06-05 2008-03-13 Cryo-Cell International, Inc. Procurement, isolation and cryopreservation of maternal placental cells
WO2007149493A2 (en) * 2006-06-22 2007-12-27 Immugen Inc Restoration of hearing loss
EP2054500B1 (de) 2006-08-18 2016-11-23 Ajinomoto Co., Inc. L-glutaminsäure produzierendes bakterium und verfahren zur herstellung von l-glutaminsäure
US20090286317A1 (en) * 2006-09-14 2009-11-19 Probiogen Ag Modular culture system for maintenance, differentiation and proliferation of cells
JP5537153B2 (ja) 2006-11-03 2014-07-02 アストロム バイオサイエンシーズ， インコーポレイテッド 組織修復のための混合細胞集団および細胞処理のための単離技術
NZ579050A (en) * 2007-02-06 2012-10-26 Tai June Yoo Treatment and prevention of neurodegenerative diseases using gene therapy
CN101688177A (zh) 2007-02-12 2010-03-31 人类起源公司 来自贴壁胎盘干细胞的肝细胞和软骨细胞；以及cd34+、cd45-胎盘干细胞富集的细胞群
DK2120977T3 (da) 2007-02-12 2013-08-12 Anthrogenesis Corp Behandling af inflammatoriske sygdomme under anvendelse af placenta-stamceller
WO2008121461A2 (en) * 2007-02-26 2008-10-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Vaccine for activating helper function of cd8+ tcells
ES2665024T3 (es) * 2007-03-05 2018-04-24 Terumo Bct, Inc. Métodos para controlar el movimiento celular en biorreactores de fibra hueca
CA2680130C (en) 2007-03-05 2016-01-12 Caridianbct, Inc. Cell expansion system and methods of use
AU2008236529B2 (en) * 2007-04-06 2013-09-05 Terumo Bct, Inc. Improved bioreactor surfaces
EP2148922B1 (de) * 2007-04-13 2020-03-04 Terumo BCT, Inc. Zellexpansionssystem und verfahren zu seiner verwendung
KR20230065354A (ko) 2007-09-28 2023-05-11 셀룰래리티 인코포레이티드 인간 태반 관류액 및 인간 태반-유래 중간체 천연 킬러 세포를 사용한 종양 억제 방법
ATE545033T1 (de) * 2007-10-15 2012-02-15 King S College London Diagnostische verfahren für hiv-infektion
CN101889007A (zh) * 2007-12-06 2010-11-17 日产化学工业株式会社 采用杂环化合物的造血干细胞的扩增方法
US10350243B2 (en) * 2008-01-30 2019-07-16 Memorial Sloan-Kettering Cancer Center Methods for off-the-shelf-tumor immunotherapy using allogeneic T-cell precursors
US10059923B2 (en) 2008-01-30 2018-08-28 Memorial Sloan Kettering Cancer Center Methods for off-the-shelf tumor immunotherapy using allogeneic T-cell precursors
CA2618163A1 (en) 2008-02-07 2009-08-07 K. W. Michael Siu Head and neck cancer biomarkers
CA2723114C (en) 2008-05-16 2018-02-27 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
JP6169316B2 (ja) 2008-08-20 2017-07-26 アンスロジェネシス コーポレーション 改良型細胞組成物およびその作製方法
CA2734237C (en) 2008-08-20 2019-07-02 Anthrogenesis Corporation Treatment of stroke using isolated placental cells
AU2009283161A1 (en) 2008-08-22 2010-02-25 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
US8784825B2 (en) 2008-08-28 2014-07-22 Taiga Biotechnologies, Inc. Modulators of MYC, methods of using the same, and methods of identifying agents that modulate MYC
CN107630001A (zh) 2008-11-06 2018-01-26 印第安纳大学研究与技术公司 增强造血干细胞植入过程的材料和方法
BRPI0922184A2 (pt) 2008-11-19 2020-08-18 Anthrogenesis Corporation célula isolada, população isolada de células, matriz ou estrutura sintética permanente ou decelularizada degradável, e , método para tratar um indivíduo
CA2760655C (en) 2009-06-04 2018-03-06 Nissan Chemical Industries, Ltd. Heterocyclic compounds and expansion agents for hematopoietic stem cells
JP2011045269A (ja) * 2009-08-26 2011-03-10 Hirosaki Univ 幹細胞および／または前駆細胞の培養方法
JP2013518108A (ja) 2010-01-26 2013-05-20 アントフロゲネシス コーポレーション 胎盤幹細胞を用いる骨関連癌の治療
PL2556145T3 (pl) 2010-04-07 2017-02-28 Anthrogenesis Corporation Angiogeneza z zastosowaniem łożyskowych komórek macierzystych
EP2555783A1 (de) 2010-04-08 2013-02-13 Anthrogenesis Corporation Behandlung von sarkoidose mithilfe von stammzellen aus der plazenta
CN105154394B (zh) 2010-05-05 2019-06-18 泰尔茂比司特公司 重新接种中空纤维生物反应器系统中生长的贴壁细胞的方法
KR20200077613A (ko) 2010-07-13 2020-06-30 안트로제네시스 코포레이션 천연 킬러 세포의 생성 방법
CA2807209C (en) 2010-08-16 2019-09-17 Mount Sinai Hospital Markers of the male urogenital tract
WO2012048275A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
WO2012092485A1 (en) 2010-12-31 2012-07-05 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory rna molecules
EP3443968A1 (de) 2011-06-01 2019-02-20 Celularity, Inc. Schmerzbehandlung mithilfe von stammzellen aus der plazenta
WO2013055476A1 (en) 2011-09-09 2013-04-18 Anthrogenesis Corporation Treatment of amyotrophic lateral sclerosis using placental stem cells
AU2012315699B2 (en) 2011-09-30 2017-08-17 Bluebird Bio, Inc. Compounds for improved viral transduction
US20150064273A1 (en) 2012-02-13 2015-03-05 Gamida-Cell Ltd. Mesenchymal Stem Cells Conditioned Medium and Methods of Generating and Using the Same
US8940294B2 (en) 2012-03-02 2015-01-27 Tissuetech, Inc. Methods of isolating and culturing stem cells
US9271999B2 (en) 2012-05-09 2016-03-01 Cantex Pharmaceuticals, Inc. Treatment of myelosuppression
WO2014011901A2 (en) * 2012-07-11 2014-01-16 Sangamo Biosciences, Inc. Methods and compositions for delivery of biologics
CN114645015A (zh) 2012-07-20 2022-06-21 泰加生物工艺学公司 造血区室的增强的重建和自动重建
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
EP2885393A1 (de) 2012-08-20 2015-06-24 Terumo BCT, Inc. Verfahren zum laden und verteilen von zellen in einem bioreaktor eines zellexpansionssystems
AU2014215458A1 (en) 2013-02-05 2015-08-13 Anthrogenesis Corporation Natural killer cells from placenta
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
WO2015073913A1 (en) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expanding cells in a bioreactor
EP3122866B1 (de) 2014-03-25 2019-11-20 Terumo BCT, Inc. Passives ersetzen von medien
US10077421B2 (en) 2014-04-24 2018-09-18 Terumo Bct, Inc. Measuring flow rate
US20160090569A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled Feed
WO2016133910A1 (en) 2015-02-17 2016-08-25 Cantex Pharmaceuticals, Inc. Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
WO2016133907A1 (en) * 2015-02-17 2016-08-25 Cantex Pharmaceuticals, Inc. Adoptive cell transfer methods
WO2016182034A1 (ja) * 2015-05-12 2016-11-17 株式会社オンチップ・バイオテクノロジーズ 単一粒子解析方法およびその解析のためのシステム
GB201508752D0 (en) 2015-05-21 2015-07-01 Mason Christopher And Veraitch Farlan S Cell culture device, system and methods of use thereof
AU2016281662B2 (en) * 2015-06-23 2021-12-02 Board Of Regents Of The University Of Texas System Methods and apparatus for conditioning cell populations for cell therapies
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
JP7370529B2 (ja) 2015-08-31 2023-10-30 剛士 田邊 多能性幹細胞製造システム、幹細胞の誘導方法、幹細胞の浮遊培養方法、幹細胞の浮遊培養器、人工多能性幹細胞の作製方法、及び動物細胞から特定の体細胞を作製する方法
JPWO2017061528A1 (ja) * 2015-10-09 2018-07-26 国立大学法人名古屋大学 血小板製造用デバイス、血小板製造装置及び血小板製造方法
IL261002B2 (en) 2016-02-12 2024-07-01 Bluebird Bio Inc Preparations of a VCN amplifier and methods of using them
WO2017139561A1 (en) 2016-02-12 2017-08-17 Bluebird Bio, Inc. Vcn enhancer compositions and methods of using the same
WO2017169259A1 (ja) * 2016-03-28 2017-10-05 ソニー株式会社 細胞培養容器、細胞培養システム、細胞培養キット及び細胞培養方法
JP6111510B1 (ja) 2016-05-02 2017-04-12 インテグリカルチャー株式会社 成長誘導システム、成長誘導制御装置、成長誘導制御方法、および、成長誘導制御プログラム
US11484879B2 (en) 2016-05-02 2022-11-01 Integriculture Inc. System for aging induction, control device for aging induction, method for controlling aging induction, and program for controlling aging induction
WO2017205667A1 (en) 2016-05-25 2017-11-30 Terumo Bct, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
CN113786476A (zh) 2016-12-02 2021-12-14 泰加生物工艺学公司 纳米颗粒调配物
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
CN117247899A (zh) 2017-03-31 2023-12-19 泰尔茂比司特公司 细胞扩增
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
BR112020019920A2 (pt) * 2018-03-30 2021-01-05 Dsm Ip Assets B.V. Método de redução de emulsão por lavagem de caldo
EP3952909A4 (de) 2019-04-08 2023-06-07 Taiga Biotechnologies, Inc. Zusammensetzungen und verfahren zur kryokonservierung von immunzellen

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486188A (en) * 1980-08-14 1984-12-04 Applied Medical Devices, Inc. Bone marrow transplant method and apparatus
US4481946A (en) * 1980-08-14 1984-11-13 Altshuler John H Bone marrow transplant method and apparatus
US4514499A (en) * 1983-02-04 1985-04-30 Corning Glass Works Cell culture using a monolithic support
US5032508A (en) * 1988-09-08 1991-07-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
US4963489A (en) * 1987-04-14 1990-10-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
US5032407A (en) * 1987-01-16 1991-07-16 Ohio University Edison Animal Biotechnology Center Gene transfer using transformed, neodetermined, embryonic cells
US5399493A (en) * 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
DK0477290T3 (da) * 1989-06-15 1997-07-21 Univ Michigan Fremgangsmåder, sammensætninger og indretninger til dyrkning af celler
US5061620A (en) * 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5199942A (en) * 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
NL9101680A (nl) * 1991-10-04 1993-05-03 Tno Werkwijze voor het genetisch modificeren van beenmergcellen van primaten, alsmede daarbij bruikbare cellen die recombinante retrovirale vectoren produceren.
KR950700403A (ko) * 1992-03-04 1995-01-16 죤 제이. 쉬바르츠 조혈 간세포의 배양 및 그것의 유전공학(culturing of hematopoietic stem cells and their genetic engineering)
WO1993018136A1 (en) * 1992-03-05 1993-09-16 Cytomed, Inc. Process for supporting hematopoietic progenitor cells
AU679120B2 (en) * 1993-09-03 1997-06-19 Systemix, Inc. Genetically modified human hematopoietic stem cells and their progeny

Also Published As

Publication number Publication date
ATE295412T1 (de) 2005-05-15
EP1473360A3 (de) 2005-02-02
JP2006158401A (ja) 2006-06-22
CA2100268A1 (en) 1992-06-18
AU5059296A (en) 1996-07-11
EP0575350A1 (de) 1993-12-29
JPH11221074A (ja) 1999-08-17
AU665525B2 (en) 1996-01-11
EP1473360A8 (de) 2010-07-28
EP0575350B1 (de) 2005-05-11
US5399493A (en) 1995-03-21
EP0575350A4 (en) 1997-07-02
WO1992011355A1 (en) 1992-07-09
AU687674B2 (en) 1998-02-26
EP1473360A2 (de) 2004-11-03
US5670351A (en) 1997-09-23
KR100225307B1 (ko) 1999-10-15
JPH06505151A (ja) 1994-06-16
KR930703434A (ko) 1993-11-30
CA2100268C (en) 2008-12-02
JP2000189157A (ja) 2000-07-11
JP2001120261A (ja) 2001-05-08
DE69133459T2 (de) 2006-01-19
AU9175091A (en) 1992-07-22

Similar Documents

Publication Publication Date Title
DE69133459D1 (de) Methoden für die ex-vivo replikation und stabile genetische transformation von menschlichen stamm-zellen
EP1100878B8 (de) Verfahren zur herstellung von genetisch modifizierten cd34-negativen, adhärent wachsenden hämatopoietischen stammzellen
ATE358493T1 (de) Menschliche mesenchymale stammzellen aus peripherem blut
AU2953302A (en) Human cord blood derived unrestricted somatic stem cells (ussc)
MD1639B2 (en) DNA or fragments thereof, encoding the human erythropoietin, vectors, host cells or cell lines, DNAc or fragments thereof, encoding the human erythropoietin, human recombined erythropoietin, processes for obtaining human erythropoietin and human recombined erythropoietin, pharmaceutical composition and process for obtaining thereof
CA2323073A1 (en) Uses for human non-autologous mesenchymal stem cells
FR2411889A1 (fr) Nouvelles preparations de micro-organismes et leur procede de production
DK2285D0 (da) Osteogen faktor og middel indeholdende denne faktor
KR100201663B1 (en) Methods, compositions and devices for growing cells
JP2005521405A5 (de)
DK1242578T3 (da) Celledyrkningsmedium indeholdende vækstfaktorer og L-glutamin
YU217890A (sh) Postupak za dobijanje genetskih konstrukcija za ekspresiju nervnog faktora rasta u eukariotskim ćelijama
ES2162331T3 (es) Utilizacion del factor de crecimiento del tejido nervioso para conservacion, cultivo o tratamiento de la cornea.
ES2012128A6 (es) Metodo de tratar plantas con acidos organicos que contienen azufre.
EP0349607A1 (de) Herstellung und verwendung von pflanzen mit verbessertem biologischem wert
HUP9800520A2 (hu) Génexpresszió emlős sejtekben
Fouad Dental stem cells: a perspective area in dentistry
Taichman et al. Maturation of human gingival keratinocytes cultured with fibroblasts from keratinizing and non-keratinizing epithelia
Ahuja et al. DENTAL STEM CELLS: MIRACLE CELLS OF DENTISTRY.
EP0189587A3 (en) Method of sterilizing recombinant microorganism
Ahmed et al. Tissue Engineering in Dentistry-Boom in Dentistry
JPH04501054A (ja) 所望の形質を持つ移植用培養上皮細胞
Rikitake et al. A newly established cell line derived from the human dental pulp
RU2336830C2 (ru) Способ восстановления костных структур челюсти
CN110721197A (zh) 促进毛发生长的组合物

Legal Events

Date Code Title Description
8364 No opposition during term of opposition